Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Parkinson disease”

Dual Tasking Training to Enhance Self-Efficacy in Individuals With Parkinson's DiseaseNot Yet Recruiting
NCT07611578NAUpdated May 28, 2026
Sponsor: Alvaro Reyes
Parkinson´s Disease
Chile
Continuous Wearable Monitor for the Detection and Release of Freezing of Gait.Completed
NCT06385392N/AUpdated May 28, 2026
Sponsor: HealthPartners Institute
Parkinson Disease
United States
A Study of Caregiver Connections Via Technology in DementiaActive Not Recruiting
NCT05779839NAUpdated May 28, 2026
Sponsor: Mayo Clinic
Caregiver Stress · Dementia · Alzheimer Disease · Lewy Body Dementia
United States
Early Molecular Biomarkers for Differentiating Parkinsonian SyndromesNot Yet Recruiting
NCT07604883N/AUpdated May 28, 2026
Sponsor: International Institute of Molecular and Cell Biology in Warsaw
PARKINSON DISEASE (Disorder) · Atypical Parkinsonism · Multiple System Atrophy · Progressive Supranuclear Palsy (PSP)
Poland
Use of CereGate Therapy for Freezing of Gait in PDRecruiting
NCT05292794NAUpdated May 28, 2026
Sponsor: CereGate Inc.
Parkinson Disease · Freezing of Gait · Deep Brain Stimulation
United States
Exercise Strategies in Parkinson's DiseaseEnrolling By Invitation
NCT06104397NAUpdated May 28, 2026
Sponsor: Shirley Ryan AbilityLab
Parkinson Disease
United States
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)Completed
NCT04305054Phase 1, Phase 2Updated May 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Argentina, Australia, Chile, Colombia +9 more
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)Recruiting
NCT06916507N/AUpdated May 28, 2026
Sponsor: AbbVie
Parkinson's Disease
Germany
Intestinal Immunity in Neurologic DiseaseRecruiting
NCT06329453N/AUpdated May 27, 2026
Sponsor: Yale University
Multiple Sclerosis · Parkinson Disease · REM Sleep Behavior Disorder
United States
Trunk Control Exercises and Mirror Therapy on Balance and Posture in Parkinson's DiseaseRecruiting
NCT07610031NAUpdated May 27, 2026
Sponsor: University of Lahore
Parkinson s Disease
Pakistan
Smart Wearable Device (gaitQ): Walk Better ProjectCompleted
NCT05913219N/AUpdated May 27, 2026
Sponsor: University of Exeter
Parkinson Disease · Stroke · Multiple Sclerosis · Osteoporosis
United Kingdom
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)Active Not Recruiting
NCT06602193Phase 2Updated May 27, 2026
Sponsor: Denali Therapeutics Inc.
Parkinson Disease
United States, Germany, Israel, Spain
Clinical Trail of Transcranial MR-guided Focused Ultrasound in the Treatment of Motor Symptoms in Patients With Parkinson' DiseaseCompleted
NCT06639945NAUpdated May 27, 2026
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Parkinson Disease, Idiopathic
China
Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's DiseaseCompleted
NCT04578678N/AUpdated May 26, 2026
Sponsor: Insel Gruppe AG, University Hospital Bern
Parkinson's Disease · Deep Brain Stimulation
France, Germany, Switzerland
Effects of Home-based High-speed Bodyweight Resistance Training in Individual With Parkinson's DiseaseCompleted
NCT06646523NAUpdated May 26, 2026
Sponsor: Federal University of Minas Gerais
Parkinson Disease
Brazil
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)Completed
NCT05064059Phase 3Updated May 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Colorectal Cancer
United States, Australia, Canada, Chile, China +16 more
Zesty Exercise System for Therapeutic EngagementRecruiting
NCT07382674NAUpdated May 26, 2026
Sponsor: Emory University
Parkinson Disease
United States
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active Not Recruiting
NCT04624204Phase 3Updated May 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer
United States, Australia, Belgium, Bulgaria, Canada +20 more
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active Not Recruiting
NCT05239741Phase 3Updated May 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Colorectal Neoplasms
China
Acceptability of the Somnomat Casa for the Treatment of Parkinson's DiseaseRecruiting
NCT06386497NAUpdated May 22, 2026
Sponsor: Insel Gruppe AG, University Hospital Bern
Parkinson Disease
Switzerland
SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's DiseaseRecruiting
NCT05765110NAUpdated May 22, 2026
Sponsor: Insel Gruppe AG, University Hospital Bern
Parkinson Disease
Czechia, Switzerland
Balance Tele-Rehab in Parkinson's DiseaseRecruiting
NCT05680597NAUpdated May 22, 2026
Sponsor: Oregon Health and Science University
Parkinson Disease
United States
Parkinson's Disease Biomarkers in Nerve Cells in the GutRecruiting
NCT05347407N/AUpdated May 22, 2026
Sponsor: Weill Medical College of Cornell University
Parkinson Disease
United States
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Completed
NCT03260894Phase 3Updated May 22, 2026
Sponsor: Incyte Corporation
Renal Cell Carcinoma (RCC)
United States, Australia, Brazil, Canada, Chile +15 more
Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)Completed
NCT07214285Phase 1, Phase 2Updated May 22, 2026
Sponsor: University Hospital, Lille
Parkinson Disease
France

Previous page Next page